BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 28844874)

  • 1. Cannabinoid CB
    Chen W; Liu H; Guan H; Xue N; Wang L
    Eur J Pharmacol; 2017 Nov; 814():232-239. PubMed ID: 28844874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel selective cannabinoid CB(1) receptor antagonist MJ08 with potent in vivo bioactivity and inverse agonistic effects.
    Chen W; Xu C; Liu HY; Long L; Zhang W; Zheng ZB; Xie YD; Wang LL; Li S
    Acta Pharmacol Sin; 2011 Sep; 32(9):1148-58. PubMed ID: 21841814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cannabinoid-1 Receptor Antagonist MJ08 with Different Effects in Stomach and Small Intestine.
    Yu Y; Chen W; Meng D; Zhou XM; Wang LL; Xu C
    Assay Drug Dev Technol; 2021 Apr; 19(3):176-183. PubMed ID: 33784479
    [No Abstract]   [Full Text] [Related]  

  • 4. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain.
    Erdozain AM; Diez-Alarcia R; Meana JJ; Callado LF
    Biochem Pharmacol; 2012 Jan; 83(2):260-8. PubMed ID: 22093909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase.
    Esposito I; Proto MC; Gazzerro P; Laezza C; Miele C; Alberobello AT; D'Esposito V; Beguinot F; Formisano P; Bifulco M
    Mol Pharmacol; 2008 Dec; 74(6):1678-86. PubMed ID: 18801918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of in vitro antagonism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle.
    Lindborg KA; Teachey MK; Jacob S; Henriksen EJ
    Diabetes Obes Metab; 2010 Aug; 12(8):722-30. PubMed ID: 20590750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterisation of the CB
    Mazeh AC; Angus JA; Wright CE
    Eur J Pharmacol; 2021 Oct; 909():174433. PubMed ID: 34416240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice.
    Bajzer M; Olivieri M; Haas MK; Pfluger PT; Magrisso IJ; Foster MT; Tschöp MH; Krawczewski-Carhuatanta KA; Cota D; Obici S
    Diabetologia; 2011 Dec; 54(12):3121-31. PubMed ID: 21987346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.
    Merroun I; Sánchez-González C; Martínez R; López-Chaves C; Porres JM; Aranda P; Llopis J; Galisteo M; Zarzuelo A; Errami M; López-Jurado M
    Metabolism; 2013 Nov; 62(11):1641-50. PubMed ID: 23932644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced function of inhibitory presynaptic cannabinoid CB1 receptors on sympathetic nerves of DOCA-salt hypertensive rats.
    Toczek M; Schlicker E; Grzęda E; Malinowska B
    Life Sci; 2015 Oct; 138():78-85. PubMed ID: 25921770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of Gα i/o inhibition.
    Wu HM; Yang YM; Kim SG
    Mol Pharmacol; 2011 Nov; 80(5):859-69. PubMed ID: 21803969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants.
    Jourdan T; Demizieux L; Gresti J; Djaouti L; Gaba L; Vergès B; Degrace P
    Hepatology; 2012 Mar; 55(3):790-9. PubMed ID: 21987372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
    Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
    J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Search for an endogenous cannabinoid-mediated effect in the sympathetic nervous system.
    Pfitzer T; Niederhoffer N; Szabo B
    Naunyn Schmiedebergs Arch Pharmacol; 2005 Jan; 371(1):9-17. PubMed ID: 15660243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice.
    Nam DH; Lee MH; Kim JE; Song HK; Kang YS; Lee JE; Kim HW; Cha JJ; Hyun YY; Kim SH; Han SY; Han KH; Han JY; Cha DR
    Endocrinology; 2012 Mar; 153(3):1387-96. PubMed ID: 22234468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.
    Jacobson LH; Commerford SR; Gerber SP; Chen YA; Dardik B; Chaperon F; Schwartzkopf C; Nguyen-Tran V; Hollenbeck T; McNamara P; He X; Liu H; Seidel HM; Jaton AL; Gromada J; Teixeira S
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Dec; 384(6):565-81. PubMed ID: 21947251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.
    Chen W; Chen Z; Xue N; Zheng Z; Li S; Wang L
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Aug; 386(8):721-32. PubMed ID: 23620336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats.
    Järbe TU; DiPatrizio NV; Li C; Makriyannis A
    Behav Pharmacol; 2007 Nov; 18(7):673-80. PubMed ID: 17912052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse.
    Fride E; Braun H; Matan H; Steinberg S; Reggio PH; Seltzman HH
    Pediatr Res; 2007 Nov; 62(5):533-6. PubMed ID: 17805201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice.
    Bell-Anderson KS; Aouad L; Williams H; Sanz FR; Phuyal J; Larter CZ; Farrell GC; Caterson ID
    Int J Obes (Lond); 2011 Dec; 35(12):1539-48. PubMed ID: 21386801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.